 |
Photo courtesy of Yonhap News |
[Alpha Biz= Paul Lee] SEOUL, August 21, 2025 – Samsung Biologics announced today that it has received preliminary approval from the Korea Exchange for the relisting of its planned spin-off entity, tentatively named Samsung Epis Holdings. The move marks a strategic restructuring to strengthen its dual growth engines in contract development and manufacturing (CDMO) and new drug development.
Following the spin-off, Samsung Biologics will operate as a pure-play CDMO, while Samsung Epis Holdings will take over responsibility for biosimilar and novel drug development through full ownership of Samsung Bioepis.
Under the approved share allocation plan, existing Samsung Biologics shareholders will receive shares in both companies at a ratio of 0.6503913 (Samsung Biologics) to 0.3496087 (Samsung Epis Holdings), based on current book value of net assets. Any fractional shares generated will be repurchased by the company and compensated in cash within five business days, calculated on the first day’s closing price after relisting.
The Korea Exchange ruling clears a key regulatory hurdle for Samsung Biologics’ restructuring plan. Analysts have responded positively, with several securities firms raising target prices on expectations that the combined post-spin-off valuations will exceed the current standalone value of Samsung Biologics. Mirae Asset Securities recently revised its target price from KRW 1.35 million to KRW 1.4 million, citing the company’s robust growth trajectory.
On August 21, Samsung Biologics shares closed at KRW 1,017,000, down 0.2% from the previous session.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
